Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans.
| العنوان: | Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans. |
|---|---|
| المؤلفون: | Addetia A; Molecular and Cellular Biology Graduate Program, University of Washington, Seattle, Washington, USA.; Department of Biochemistry, University of Washington, Seattle, Washington, USA., Stewart C; Department of Biochemistry, University of Washington, Seattle, Washington, USA., Seo AJ; Department of Biochemistry, University of Washington, Seattle, Washington, USA., Sprouse KR; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA., Asiri AY; Al-Hayat National Hospital, Riyadh, Saudi Arabia., Al-Mozaini M; Department of Infection and Immunity, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia., Memish ZA; King Saud Medical City, Ministry of Health, Riyadh, Saudi Arabia.; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.; Kyung Hee University, Seoul, South Korea., Alshukairi A; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.; Department of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia., Veesler D; Department of Biochemistry, University of Washington, Seattle, Washington, USA.; Howard Hughes Medical Institute, Seattle, WA 98195, USA. |
| المصدر: | BioRxiv : the preprint server for biology [bioRxiv] 2024 Apr 02. Date of Electronic Publication: 2024 Apr 02. |
| نوع المنشور: | Preprint |
| اللغة: | English |
| بيانات الدورية: | Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE |
| مستخلص: | Middle-East respiratory syndrome coronavirus (MERS-CoV) first emerged in 2012 and causes human infections in endemic regions. Most vaccines and therapeutics in development against MERS-CoV focus on the spike (S) glycoprotein to prevent viral entry into target cells. These efforts, however, are limited by a poor understanding of antibody responses elicited by infection along with their durability, fine specificity and contribution of distinct S antigenic sites to neutralization. To address this knowledge gap, we analyzed S-directed binding and neutralizing antibody titers in plasma collected from individuals infected with MERS-CoV in 2017-2019 (prior to the COVID-19 pandemic). We observed that binding and neutralizing antibodies peak 1 to 6 weeks after symptom onset/hospitalization, persist for at least 6 months, and broadly neutralize human and camel MERS-CoV strains. We show that the MERS-CoV S |
| References: | Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. (PMID: 28807998) Science. 2021 Aug 6;373(6555):648-654. (PMID: 34210893) Cell. 2020 Nov 25;183(5):1367-1382.e17. (PMID: 33160446) Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. (PMID: 33592168) Nature. 2013 Mar 14;495(7440):251-4. (PMID: 23486063) Science. 2021 Sep 03;373(6559):1109-1116. (PMID: 34344823) Front Microbiol. 2022 Sep 28;13:988298. (PMID: 36246239) Nat Microbiol. 2022 Jul;7(7):1063-1074. (PMID: 35773398) Cell. 2021 Oct 14;184(21):5432-5447.e16. (PMID: 34619077) Cell. 2021 Apr 29;184(9):2332-2347.e16. (PMID: 33761326) Lancet Infect Dis. 2020 Jul;20(7):816-826. (PMID: 32325038) Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507) Science. 2022 Aug 12;377(6607):735-742. (PMID: 35857703) mBio. 2016 Mar 01;7(2):e00019. (PMID: 26933050) Nat Struct Mol Biol. 2019 Dec;26(12):1151-1157. (PMID: 31792450) Nature. 2021 Oct;598(7880):342-347. (PMID: 34464958) Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):. (PMID: 34099556) Emerg Microbes Infect. 2019;8(1):516-530. (PMID: 30938227) Sci Rep. 2022 Jan 24;12(1):1260. (PMID: 35075213) Viruses. 2022 Aug 09;14(8):. (PMID: 36016365) N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945) Cell Res. 2015 Nov;25(11):1237-49. (PMID: 26391698) Nature. 2013 Aug 8;500(7461):227-31. (PMID: 23831647) Nature. 2020 Oct;586(7830):567-571. (PMID: 32756549) Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8. (PMID: 26216974) Cell. 2023 Feb 16;186(4):850-863.e16. (PMID: 36803605) Sci Immunol. 2020 Jun 11;5(48):. (PMID: 32527802) Cell Res. 2022 Dec;32(12):1068-1085. (PMID: 36357786) Nature. 2023 Sep;621(7979):592-601. (PMID: 37648855) Sci Transl Med. 2014 Apr 30;6(234):234ra59. (PMID: 24778414) Emerg Infect Dis. 2016 Oct;22(10):1824-6. (PMID: 27332149) EClinicalMedicine. 2021 Nov;41:101191. (PMID: 34805807) Science. 2022 Aug 19;377(6608):890-894. (PMID: 35857529) J Virol. 2016 Dec 16;91(1):. (PMID: 27795425) Cell Rep. 2019 Sep 24;28(13):3395-3405.e6. (PMID: 31553909) Sci Immunol. 2017 Aug 4;2(14):. (PMID: 28778905) N Engl J Med. 2012 Nov 8;367(19):1814-20. (PMID: 23075143) Elife. 2018 Jan 16;7:. (PMID: 29336306) Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):E8508-E8517. (PMID: 28923942) Nat Commun. 2015 Jul 28;6:7712. (PMID: 26218507) N Engl J Med. 2003 May 15;348(20):1967-76. (PMID: 12690091) Emerg Infect Dis. 2021 May;27(5):. (PMID: 33900908) Nature. 2021 Sep;597(7874):97-102. (PMID: 34261126) Nat Commun. 2019 Jul 11;10(1):3068. (PMID: 31296843) Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26. (PMID: 24778221) Cell Rep. 2018 Jul 10;24(2):441-452. (PMID: 29996104) mBio. 2018 Oct 30;9(5):. (PMID: 30377284) Science. 2021 Dec 24;374(6575):1621-1626. (PMID: 34751595) Nature. 2022 Dec;612(7941):748-757. (PMID: 36477529) Sci Transl Med. 2023 Sep 27;15(715):eadg5567. (PMID: 37756379) Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11157-11162. (PMID: 29073020) Elife. 2023 Mar 21;12:. (PMID: 36942851) J Virol. 2019 Jan 4;93(2):. (PMID: 30404801) Adv Virus Res. 2019;105:93-116. (PMID: 31522710) Science. 2020 Nov 20;370(6519):950-957. (PMID: 32972994) Lancet Infect Dis. 2020 Jul;20(7):827-838. (PMID: 32325037) Immunity. 2023 Mar 14;56(3):669-686.e7. (PMID: 36889306) Nat Struct Mol Biol. 2021 Jun;28(6):478-486. (PMID: 33981021) PLoS Pathog. 2017 Jul 31;13(7):e1006546. (PMID: 28759649) Euro Surveill. 2012 Oct 04;17(40):20290. (PMID: 23078800) Cell Res. 2013 Aug;23(8):986-93. (PMID: 23835475) Cell Rep. 2021 Nov 2;37(5):109929. (PMID: 34710354) Ann Intern Med. 2014 Mar 18;160(6):389-97. (PMID: 24474051) Sci Immunol. 2022 Dec 23;7(78):eadf1421. (PMID: 36356052) PLoS Pathog. 2022 Jun 29;18(6):e1010592. (PMID: 35767821) Lancet Infect Dis. 2019 Sep;19(9):1013-1022. (PMID: 31351922) Emerg Infect Dis. 2017 Jul;23(7):1079-1084. (PMID: 28585916) Nature. 2020 Dec;588(7839):682-687. (PMID: 33045718) Cell. 2020 Nov 12;183(4):1024-1042.e21. (PMID: 32991844) Emerg Infect Dis. 2015 Dec;21(12):2186-9. (PMID: 26583829) J Infect Dis. 2021 Feb 3;223(2):197-205. (PMID: 33535236) Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9. (PMID: 25288733) Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12262-12267. (PMID: 27791014) Clin Microbiol Infect. 2022 Feb;28(2):292-296. (PMID: 34139334) EBioMedicine. 2022 Dec;86:104341. (PMID: 36375316) Cell Rep. 2023 Jun 27;42(6):112621. (PMID: 37300832) PLoS Pathog. 2022 Feb 8;18(2):e1010248. (PMID: 35134084) Cell. 2019 Feb 21;176(5):1026-1039.e15. (PMID: 30712865) Lancet. 2003 Apr 19;361(9366):1319-25. (PMID: 12711465) Sci Transl Med. 2022 Jul 27;14(655):eabn3715. (PMID: 35895836) |
| معلومات مُعتمدة: | 75N93022C00036 United States AI NIAID NIH HHS; DP1 AI158186 United States AI NIAID NIH HHS; P01 AI167966 United States AI NIAID NIH HHS |
| تواريخ الأحداث: | Date Created: 20240415 Latest Revision: 20240425 |
| رمز التحديث: | 20240425 |
| مُعرف محوري في PubMed: | PMC11014493 |
| DOI: | 10.1101/2024.03.31.586409 |
| PMID: | 38617298 |
| قاعدة البيانات: | MEDLINE |
| DOI: | 10.1101/2024.03.31.586409 |
|---|